Endogenous angiogenesis inhibitors

APMIS

Volumn 112, Issue 7-8, 2004, Pages 496-507

  Folkman, Judah ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Angiogenesis inhibitors; Antiangiogenic therapy; Endogenous angiogenesis inhibitors; Metronomic chemotherapy

Indexed keywords

2 (8 HYDROXY 6 METHOXY 1 OXO 1H 2 BENZOPYRAN 3 YL)PROPIONIC ACID; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; ANTITHROMBIN III; APOPTOSIS INDUCING FACTOR; ARRESTEN; AXITINIB; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; BORTEZOMIB; CANCER VACCINE; CANSTATIN; CELECOXIB; CETUXIMAB; ENDOSTATIN; ERLOTINIB; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; MONOCLONAL ANTIBODY LM 609; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PIGMENT EPITHELIUM DERIVED FACTOR; SEMAXANIB; SORAFENIB; SUNITINIB; TELOMERASE INHIBITOR; TETRAHYDROCORTISOL; THALIDOMIDE; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR ALPHA; TUMSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VATALANIB;

ANGIOGENESIS; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; COLON CANCER; DIABETIC RETINOPATHY; DRUG MECHANISM; EXTRACELLULAR MATRIX; GENE THERAPY; GIANT CELL TUMOR; HEMANGIOMATOSIS; HUMAN; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; RETINA MACULA DEGENERATION; REVIEW; TUMOR SUPPRESSOR GENE; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; GENES, TUMOR SUPPRESSOR; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 10344220521     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2004.apm11207-0809.x     Document Type: Review

References (87)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
2. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972;175:409-16.
3. Gimbrone MA Jr, Cotran RS, Folkman J. Endothelial regeneration: studies with human endothelial cells in culture. Ser Haematol 1973;6:453-5.
4. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973;52: 2745-56.
5. Folkman J. Tumor Angiogenesis. In: Holland J, Frei E III, Bast RC Jr, Kufe DW, Pollock RE, Weichselbaum RR, editors. Cancer Medicine, 5th ed. Ontario: B.C. Decker Inc.; 2000:132-52.
6. Folkman J, Kalluri R. Tumor Angiogenesis. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC Jr, Holland JF, Frei E III, editors. Cancer Medicine, 6th ed. Hamilton, Ontario: B.C. Decker; 2003:161-94.
7. Shing Y, Folkman J, Sullivan R, Butterfield C, Murray J, Klagsbrun M. Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science 1984;223:1296-9.
8. Burgess WH, Mehlman T, Marshak DR, Fraser BA, Maciag T. Structural evidence that endothelial cell growth factor beta is the precursor of both endothelial cell growth factor alpha and acidic fibroblast growth factor. Proc Natl Acad Sci USA 1986;83:7216-20.
9. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219: 983-5.
10. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
11. White CW, Sondheimer HM, Crouch EC, Wilson H, Fan LL. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med 1989;320:1197-200.
12. Folkman J. Successful treatment of an angiogenic disease. N Engl J Med 1989;320:1211-2.
13. Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science 1980;208:516-8.
14. Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis. Nature 1982;297:307-12.
15. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985;230: 1375-8.
16. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990;348:555-7.
17. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
18. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88: 277-85.
19. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5.
20. Folkman J, Mulliken JB, Ezekowitz RA. Antiangiogenic therapy of haemangiomas with interferon. In: Stuart-Harris R, Penny R, editors. The Clinical Applications of the Interferons. London: Chapman & Hall Medical 1997:255-65.
21. Kaban LB, Mulliken JB, Ezekowitz RA, Ebb D, Smith PS, Folkman J. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics 1999;103:1145-9.
22. Marier JJ, Rubin JB, Trede NS, Connors S, Grier H, Upton J, et al. Successful antiangiogenic therapy of giant cell angioblastoma with interferon alpha 2b: report of 2 cases. Pediatrics 2002; 109:E37.
23. Kaban LB, Troulis MJ, Ebb D, August M, Hornicek FJ, Dodson TB. Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws. J Oral Maxillofac Surg 2002;60:1103-11.
24. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
25. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
26. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62:4996-5000.
27. Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2002;1:1243-53.
28. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7:1419-28.
29. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459-65.
30. Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000;60:2926-35.
31. Vacca A, Ria R, Semeraro F, Merchionne F, Coluccia M, Boccarelli A, et al. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood 2003;102:3340-8.
32. Bertolini F, Mingrone W, Alietti A, Ferrucci PF, Cocorocchio E, Peccatori F, et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Ann Oncol 2001;12:987-90.
33. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57: 963-9.
34. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
35. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24.
36. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-7.
37. Marx GM, Steer CB, Harper P, Pavlakis N, Rixe O, Khayat D. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock! J Clin Oncol 2002;20:1446-8.
38. Kuenen BC, Levi M, Meijers JC, van Hinsbergh VW, Berkhof J, Kakkar AK, et al. Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. J Clin Oncol 2003;21:2192-8.
39. Satchi-Fainaro R, Puder M, Davies JW, Tran HT, Sampson DA, Greene AK, et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 2004;10:255-61.
40. Wickstrom SA, Alitalo K, Keski-Oja J. Endostatin associates with integrin alpha 5 beta1 and caveolin-1, and activates Src via a tyrosyl phosphatasedependent pathway in human endothelial cells. Cancer Res 2002;62:5580-9.
41. Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci USA 2003;100: 4766-71.
42. Abdollahi A, Hahnfeldt P, Maercker C, Grone HJ, Debus J, Ansorge W, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004;13: 649-63.
43. O'Reilly MS, Pine-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999;285:1926-8.
44. Lentzsch S, Rogers MS, LeBlanc R, Birsner AE, Shah JH, Treston AM, et al. S-3-Aminophthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res 2002;62:2300-5.
45. Kisker O, Onizuka S, Becker CM, Fannon M, Flynn E, D'Amato R, et al. Vitamin D binding protein-macrophage activating factor (BBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 2003;5:32-40.
46. Dvorak HF, Gresser I. Microvascular injury in pathogenesis of interferoninduced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst 1989;81:497-502.
47. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987;47:5155-61.
48. Folkman J. Discussion: antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws. J Oral Maxillofac Surg 2002;60:1111-3.
49. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for lifethreatening hemangiomas of infancy. N Engl J Med 1992;326:1456-63.
50. Ginns LC, Roberts DH, Mark EJ, Brusch JL, Marier JJ. Pulmonary capillary hemangiomatosis with atypical endotheliomatosis: successful antiangiogenic therapy with doxycycline. Chest 2003;124:2017-22.
51. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995;92:4562-6.
52. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001;7:1194-201.
53. Streit M, Riccardi L, Velasco P, Brown LF, Hawighorst T, Bornstein P, et al. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci USA 1999;96:14888-93.
54. Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grunkemeyer JA, Ericksen MB, et al. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 2000;275:21340-8.
55. Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C, et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaVbeta3 integrin. Cancer Cell 2003;3:589-601.
56. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002;6:1-12.
57. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-4.
58. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxiainducible factor 1alpha. Genes Dev 2000;14: 34-14.
59. Zhang L, Yu D, Hu M, Xiong S, Lang A, Ellis LM, et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res 2000;60:3655-61.
60. Sherif ZA, Nakai S, Pirollo KF, Rait A, Chang EH. Downmodulation of bFGF-binding protein expression following restoration of p53 function. Cancer Gene Ther 2001;8:771-82.
61. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 2002;359:1019-25.
62. Zorick TS, Mustacchi Z, Bando SY, Zatz M, Moreira-Filho CA, Olsen B, et al. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur J Hum Genet 2001;9:811-4.
63. Fulcher T, Griffin M, Crowley S, Firth R, Acheson R, O'Meara N. Diabetic retinopathy in Down's syndrome. Br J Ophthalmol 1998;82:407-9.
64. Chadefaux B, Ceballos I, Hamet M, Coude M, Poissonnier M, Kamoun P, et al. Is absence of atheroma in Down syndrome due to decreased homocysteine levels? Lancet 1988;2:741.
65. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999;99:1726-32.
66. Moulton KS, Olsen BR, Sonn S, Fukai N, Zurakowski D, Zeng X. Loss of collagen XVIII enhances neovascularization and vascular permeability in atherosclerosis. Circulation 2004; 110:1330-6.
67. Hesser BA, Liang XH, Camenisch G, Yang S, Lewin DA, Scheller R, et al. Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. Blood 2004;104:149-58.
68. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E, et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001;61:7669-74.
69. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36.
70. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 2003;100: 12917-22.
71. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-11.
72. Ma L, del Soldato P, Wallace JL. Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance. Proc Natl Acad Sci USA 2002;99:13243-7.
73. Kalas W, Gilpin S, Yu JL, May L, Krchnakova H, Bornstein P, et al. Restoration of thrombospondin 1 expression in tumor cells harbouring mutant ras oncogene by treatment with low doses of doxycycline. Biochem Biophys Res Commun 2003;310:109-14.
74. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferatoractivated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999;274:9116-21.
75. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, et al. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 2002;110:923-32.
76. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA. ADAM 12 cleaves ECM proteins: Correlation with cancer status and stage. J Biol Chem, Sep 2004; in press.
77. Klement G, Kikuchi L, Kieran M, Almog N, Yip T, Folkman J. Early tumor detection using platelet uptake of angiogenesis regulators. Blood 2004;104, abstract in press.
78. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-61.
79. D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 1994;91:3964-8.
80. Colorado PC, Torre A, Kamphaus G, Maeshima Y, Hopfer H, Takahashi K, et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 2000;60:2520-6.
81. Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, Torre A, et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000;275:1209-15.
82. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245-8.
83. Staton CA, Brown NJ, Rodgers GR, Corke KP, Tazzyman S, Underwood JC, et al. Alphastatin, a 24-amino acid fragment of human fibrinogen, is a potent new inhibitor of activated endothelial cells in vitro and in vivo. Blood 2004;103:601-6.
84. Albig AR, Schiemann WP. Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells. DNA Cell Biol 2004;23:367-79.
85. Streit M, Riccardi L, Velasco P, Brown LF, Hawighorst T, Bornstein P, et al. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci USA 1999;96:14888-93.
86. Stetler-Stevenson WG, Krutzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 1989;264:17374-8.
87. Olsson AK, Larsson H, Dixelius J, Johansson I, Lee C, Oellig C, et al. A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization. Cancer Res 2004;64:599-605.